Patents Assigned to AstraZeneca
  • Quinazoline derivatives as antiproliferative agents
    Patent number: 7838530
    Abstract: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: November 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • CHEMICAL COMPOUNDS 751
    Publication number: 20100292222
    Abstract: The invention concerns bicyclic compounds of Formula (I) wherein, R1, R2, R3, R4, R5, X1, X2, Y, k, m, n and p are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: May 10, 2010
    Publication date: November 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow
  • Bis-(Sulfonylamino) Derivatives in Therapy
    Publication number: 20100292279
    Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Johan Bylund, Maria E. Ek, Jörg Holenz, Annika Kers, Liselotte Öhberg
  • Novel Compounds for A-Beta-Related Pathologies
    Publication number: 20100292210
    Abstract: The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with ?-secretase and/or its substrate and hence modulate the formation of A? peptides.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 18, 2010
    Applicant: AstraZeneca AB
    Inventors: Yvonne Lo-Alfredsson, Kim Paulsen, Laszlo Rakos, Didier Rotticci, Magnus Waldman
  • Diagnostic system and method
    Patent number: 7835922
    Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: November 16, 2010
    Assignee: AstraZeneca AB
    Inventors: Fumihiko Sakai, Minoru Hosoda, Itsurou Kobayashi, Shinji Kutukake, Hareaki Yamamoto, Yoneyuki Kobayashi, Kouhei Yamashita, Hajime Baba, Masahiro Kitamura, Toshiyuki Shimizu, Yasuzumi Shimizu
  • PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY
    Publication number: 20100286181
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: August 16, 2007
    Publication date: November 11, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gregory Basarab, Pamela Hill, Kenneth Gregory Hull
  • New Compounds
    Publication number: 20100286202
    Abstract: The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 14, 2009
    Publication date: November 11, 2010
    Applicant: AstraZeneca AB
    Inventors: Yevgeni Besidski, Martin Nylöf, Inger Kers, Karin Skogholm, Shawn Johnstone, Paul Jones, Denis Labrecque, Andrew Griffin
  • Process
    Patent number: 7829123
    Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: November 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Goran Eric Sundholm, Mustafa Demirbuker, Saeed Moshashaee
  • Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy
    Patent number: 7829707
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
  • Therapeutic combinations of antihypertensive and antiangiogenics agents
    Patent number: 7829573
    Abstract: The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compositions comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: November 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Jon Owen Curwen, Donald James Ogilvie
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Publication number: 20100280048
    Abstract: The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 4, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Debra Ainge, David Chapman, Martin Lindsjo, Hans Lonn, Michael Lundkvist, Magnus Munck AF Rosen-Schold, Antonios Nikitidis, John Pavey
  • NOVEL COMPOUNDS 660
    Publication number: 20100278835
    Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).
    Type: Application
    Filed: March 9, 2010
    Publication date: November 4, 2010
    Applicants: ASTRAZENECA UK LIMITED, ARROW THERAPEUTICS LIMITED
    Inventors: Helen Blade, Heather Marie Jackson, Gary Peter Tomkinson, Elisa Ann Carron, James Andrew Lumley, Christopher John Pilkington, Alexander James Floyd Thomas, Justin Warne
  • Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators
    Publication number: 20100280082
    Abstract: Compounds of Formula (I) wherein R1, R2, R3 R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 5, 2008
    Publication date: November 4, 2010
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • THERAPEUTIC AGENTS 713
    Publication number: 20100280000
    Abstract: Disclosed herein are compounds of formula I in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: AstraZeneca AB
    Inventors: Lars Anders Mikael JOHANSSON, Robert Andrew Judkins, Lanna Li, Bjorn Christian Ingvar Lofberg, Joachim Persson
  • Spectroscopic method
    Patent number: 7825668
    Abstract: A method related to a process for treating pharmaceutical contents in a pharmaceutical processing vessel is provided. The contents have a number of predefined parameters of variable values. According to the method electromagnetic radiation of various frequencies is transmitted into the vessel and its contents. Electromagnetic radiation which has interacted with the contents is received. Based on the received electromagnetic radiation, a respective value of a physical quantity related to the contents is determining for a plurality of said frequencies. A combination of values of said predefined parameters which would, for said plurality of frequencies, approximately result in the determined values of said physical quantity is determined.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: November 2, 2010
    Assignee: AstraZeneca AB
    Inventors: Staffan Folestad, Lubomir Gradinarsky
  • SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733
    Publication number: 20100273805
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: April 21, 2010
    Publication date: October 28, 2010
    Applicant: AstraZeneca AB
    Inventors: Kenneth Granberg, Bjorn Holm
  • Crystalline forms
    Patent number: 7820645
    Abstract: There are provided crystalline forms of the compounds Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OMe) and Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OH), pharmaceutical compositions containing them, processes for obtaining them and their use in medical treatment.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: Bengt Leonard Åslund, Stefan Bengtsson, Gudrun Anita Bergman, Ursula Renata Maria Hohlneicher, Bo Ingvar Ymén
  • N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-?1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent
    Patent number: 7820679
    Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: David William Tonge, Sian Tomiko Taylor, Francis Thomas Boyle, Andrew Mark Hughes, Donna Johnstone, Marianne Bernice Ashford, Nigel Charles Barrass
  • 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 7820683
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Bernard Christophe Barlaam, Richard Ducray
  • Inhaler device counter
    Patent number: 7819075
    Abstract: Inhaler counter (20) comprising a counter housing (390), a rocker arm (200) with a pawl (210), the rocker arm being pivotally supported by the housing and arranged to perform a rocker movement in response to a linear actuation motion, a return spring (220) for resetting the rocker arm, a ratchet wheel (230) engagable with the pawl to convert the movement of the rocker arm into an incremental rotational motion of an axle arrangement (240) advancing a display means (60), the axle arrangement further comprising a back rotation prevention means (280) in the form of a spring loaded friction brake and a worm gear, the display means comprising rotatable indicator means (120) with teeth that engage the worm-gear and a stationary scale.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: Nic Bowman, Douglas Bradshaw, Lennart Sörby